Free weekly newsletter
Get the free weekly funding digest
The new funding rounds, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New funding rounds, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Industry Trends
See who's moving and how much in your market
No credit card required Weekly funding digest
Halia Therapeutics Announces $30M Series C Financing to Advance Novel Pipeline of Anti-Inflammatory Therapeutics
PRIVATEJan 31, 2024•over 2 years ago
Amount Raised
$30 Million
Investors
Todd Pedersen
Description
Halia Therapeutics announced the completion of a $30 million Series C financing led by Todd Pedersen, with continued participation from existing investors. The funds will support the advancement of lead programs in Phase II clinical trials, evaluating HT-6184, Halia's first-in-class NLRP3/NEK7 inflammasome inhibitor, and advancing additional programs into the clinic.
Related People
Suggested for you
1 contactFunding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech
Watching Halia Therapeutics? See every signal — funding, hires, M&A, contracts, sentiment.
Request a demoChoose your plan